Tags : P-lll

Akebia Presents Results of Vadadustat in P-lll INNO2VATE Program for

Shots: The global program includes two P-III studies assessing vadadustat (PO) vs darbepoetin alfa (inj.) in a ratio (1:1) in incident dialysis patients (Correction/Conversion) and prevalent dialysis patients (Conversion), in ~3,923 adult patients on dialysis with anemia due to CKD The presentation expands on previously reported positive data showing vadadustat achieved clear and consistent results […]Read More

Janssen Reports Five-Year Data of Stelara (ustekinumab) in P-lll LTE

Shots: The P-lll IM-UNITI LTE study involves assessing of Stelara (SC, 90mg, q8w/q12w) vs PBO as maintenance therapy in 1,281 patients with moderate to severe CD. All patients completing 44wks. were eligible to enter the LTE program, continuing their current regimen ~252wks. 50%+ patients were randomized to q8w dosing and continued to receive this dosage […]Read More

Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study

Shots:   The P-III Jupiter-02 Study involve assessing of Toripalimab vs PBO in combination with + Gemcitabine/ Cisplatin for 1L treatment of 289 patients with recurrent or metastatic NPC The study resulted in meeting its pre-specified 1EPs of PFS and has expanded the PFS. The company will submit the BLA to NMPA & other countries Toripalimab […]Read More